Five things for pharma marketers to know: Friday, June 22, 2018

Share this content:

Opioid supply levels have dropped in most states. A report from healthcare consulting firm Avalere found supply levels were 11% lower in 2017 than the year before. States that have passed laws limiting opioid prescriptions have seen the greatest decline. Idaho was the only state where prescriptions increased. (BioPharma Dive)


Health and Human Services Secretary Alex Azar is taking heat for attending a college reunion while immigrant families were separated at the border. HHS is responsible for housing children separated from their parents. As the crisis escalated, Azar reportedly left Washington, D.C., to attend his college reunion at Dartmouth College. (MSNBC)

The FDA accepted Bristol-Myers Squibb's latest new indication application for Opdivo and Yervoy to treat patients with advanced non-small cell lung cancer. The decision puts the company in the race with Merck's Keytruda to treat lung cancer. (Endpoints)


CVS CEO Larry Merlo is confident its acquisition of Aetna will close this year. The proposed $69 billion deal is making its way through regulatory processes. It has faced criticism that it will lower competition. (CNBC)


Johnson & Johnson opened a biotech incubator in New York. It is J&J's 10th JLABS center. It's also the latest sign of New York City's emergence as a biotech hub. (Endpoints News)


Share this content:
Scroll down to see the next article